The recent therapeutic data surrounding Eclatutug ALE-C04, an agent specifically focused on Claudin 1 (CLDN 1), indicates a significant development in the arena of malignant treatment. Until now, CLDN1-targeted methods have experienced obstacles, but this novel intervention appears to resolve som